Biomarker study of ARB-1598 in chronically infected HBV patients

Trial Profile

Biomarker study of ARB-1598 in chronically infected HBV patients

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 09 Mar 2016 According to an Arbutus Biopharma media release,the company is planning to initiate in the second half of 2016.
    • 13 Jan 2016 New trial record
    • 10 Jan 2016 According to Arbutus media release, company is planning to initiate this trial in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top